Decorin improves human pancreatic β-cell function and regulates ECM expression in vitro.

Area of Science:

• * Regenerative Medicine
• * Molecular Biology
• * Endocrinology

Background:

• * Islet transplantation is a potential therapy for type 1 diabetes.
• * Cell survival and function post-transplantation are critical challenges.
• * The pancreatic extracellular matrix (ECM) microenvironment influences beta-cell function.

Purpose of the Study:

• * To investigate the role of decorin (DCN) in human beta-cell insulin secretion.
• * To assess DCN's impact on pancreatic ECM protein expression in vitro.
• * To evaluate DCN's efficacy in an islet transplantation model.

Main Methods:

• * Next-generation sequencing to analyze gene expression changes.
• * Raman microspectroscopy and imaging for cellular and ECM analysis.
• * In vitro culture of human beta-cells and pseudo-islets encapsulated in collagen type 1.

Main Results:

• * DCN treatment upregulated glucose metabolism pathways, including mitochondrial oxidative phosphorylation.
• * DCN affected endoplasmic reticulum proteins and lipids.
• * DCN-treated encapsulated pseudo-islets demonstrated improved function in a transplantation setting.
• * DCN reduced the expression of ECM proteins associated with fibrotic capsule formation.

Conclusions:

• * Decorin (DCN) significantly improves insulin secretion and viability of human beta-cells.
• * DCN modulates the pancreatic ECM, potentially mitigating fibrotic responses.
• * DCN represents a promising therapeutic agent for enhancing islet transplantation success in type 1 diabetes.